Comment le ratio PE de 0TDF se compare-t-il à celui de ses pairs ?

0TDF offre un bon rapport qualité-prix en fonction de son ratio Price-To-Earnings ( 19.2 x) par rapport à la moyenne des pairs ( 22.7 x).

Comment le ratio PE de 0TDF se compare-t-il à celui d'autres entreprises du secteur European Pharmaceuticals ?

0TDF offre un bon rapport qualité-prix en fonction de son ratio Price-To-Earnings ( 19.2 x) par rapport à la moyenne du secteur UK Pharmaceuticals ( 32.1 x).

Quel est le ratio PE de 0TDF par rapport à son ratio équitable PE? Il s'agit du ratio PE attendu, compte tenu des prévisions de croissance des bénéfices de l'entreprise, des marges bénéficiaires et d'autres facteurs de risque.

0TDF présente un bon rapport qualité-prix en fonction de son ratio Price-To-Earnings ( 19.2 x) par rapport au ratio équitable Price-To-Earnings estimé ( 37.1 x).

Quel est le juste prix de 0TDF si l'on considère ses flux de trésorerie futurs ? Pour cette estimation, nous utilisons un modèle d'actualisation des flux de trésorerie.

0TDF ( $35.86 ) se négocie en dessous de notre estimation de la [[juste valeur]] ( $97.56 )

Quelles sont les prévisions à 12 mois des analystes et avons-nous une confiance statistique dans l'objectif de prix du consensus ?

Données insuffisantes pour afficher les prévisions de prix.

Roche Holding (LSE:0TDF) - Cours de l'action, nouvelles et analyse

0TDF Aperçu des actions

Roche Holding AG exerce des activités pharmaceutiques et diagnostiques en Europe, en Amérique du Nord, en Amérique latine, en Asie, en Afrique, en Australie et en Océanie. Plus de détails

0TDF analyse fondamentale
Score flocon de neige
Évaluation	5/6
Croissance future	3/6
Performances passées	0/6
Santé financière	3/6
Dividendes	5/6

Récompenses

Se négocie à 63.2% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 11.19% par an

Verse un dividende fiable de 3.76%

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

A un niveau d'endettement élevé

Des éléments non récurrents importants ayant un impact sur les résultats financiers

Roche Holding AG Concurrents

AstraZeneca

LSE:AZN

UK£164.5b

GSK

LSE:GSK

UK£54.5b

Hikma Pharmaceuticals

LSE:HIK

UK£4.3b

Novartis

SWX:NOVN

CHF 186.5b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Roche Holding
Historique des cours de bourse
Prix actuel de l'action	CHF 35.86
Plus haut sur 52 semaines	CHF 41.85
Plus bas sur 52 semaines	CHF 29.27
Bêta	0.15
1Variation sur 1 mois	-10.93%
Variation sur 3 mois	-14.31%
Variation sur 1 an	6.41%
3Variation sur 3 ans	-27.45%
Variation sur 5 ans	-6.08%
Évolution depuis l'introduction en bourse	16.09%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	0TDF	GB Pharmaceuticals	GB Marché
7D	0.9%	4.4%	1.7%
1Y	6.4%	2.0%	9.0%

Rendement vs Industrie: 0TDF a dépassé le secteur UK Pharmaceuticals qui a rapporté 2 % au cours de l'année écoulée.

Rendement vs marché: 0TDF a sous-performé le marché UK qui a rapporté 9 % au cours de l'année écoulée.

Volatilité des prix

Is 0TDF's price volatile compared to industry and market?
0TDF volatility
0TDF Average Weekly Movement	3.9%
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Cours de l'action stable: 0TDF n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 0TDF ( 4% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG exerce des activités pharmaceutiques et diagnostiques en Europe, en Amérique du Nord, en Amérique latine, en Asie, en Afrique, en Australie et en Océanie. L'entreprise propose des produits pharmaceutiques dans les domaines thérapeutiques suivants : anémie, tumeurs sanguines et solides, dermatologie, hémophilie, maladies inflammatoires et auto-immunes, troubles neurologiques, ophtalmologie, troubles respiratoires et transplantation. Elle développe également des produits pour divers domaines thérapeutiques.

Roche Holding AG Résumé des fondamentaux

Comment les bénéfices et les revenus de Roche Holding se comparent-ils à sa capitalisation boursière ?
0TDF statistiques fondamentales
Capitalisation boursière	US$232.61b
Bénéfices(TTM)	US$12.04b
Recettes(TTM)	US$68.67b

19.2x

Ratio P/E

3.4x

Ratio P/S

Le site 0TDF est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
0TDF compte de résultat (TTM)
Recettes	CHF 60.58b
Coût des recettes	CHF 15.43b
Marge brute	CHF 45.16b
Autres dépenses	CHF 34.54b
Les revenus	CHF 10.62b

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	13.33
Marge brute	74.54%
Marge bénéficiaire nette	17.53%
Ratio dettes/capitaux propres	104.8%

Quelles ont été les performances à long terme de 0TDF?

Voir les performances historiques et les comparaisons

Dividendes

3.8%

Rendement actuel des dividendes

72%

Ratio de distribution

0TDF Aperçu des actions

Récompenses

Analyse des risques

Roche Holding AG Concurrents

LSE:AZN

UK£164.5b

LSE:GSK

UK£54.5b

LSE:HIK

UK£4.3b

SWX:NOVN

CHF 186.5b

Historique des prix et performances

Nouvelles et mises à jour récentes

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Recent updates

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran